Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis

Zobair M. Younossi, Maria Stepanova, Quentin M. Anstee, Eric J. Lawitz, Vincent Wai-Sun Wong, Manuel Romero-Gomez, Kathryn Kersey, Georgia Li, G. Mani Subramanian, Robert P. Myers, C. Stephen Djedjos, Takeshi Okanoue, Michael Trauner, Zachary Goodman, Stephen A. Harrison

Research output: Contribution to journalArticlepeer-review

52 Scopus citations


Background: Patient-reported outcomes (PROs) are used to measure patients’ experience with their disease. However, there are few PRO data from patients with NASH. We collected data from the STELLAR clinical trials to assess PROs for NASH and advanced fibrosis. Methods: We analyzed data from 1667 patients (58 ± 9 years, 40% male, 52% with cirrhosis, 74% with diabetes) with NASH and bridging fibrosis or compensated cirrhosis (metavir scores, F3 or F4) enrolled in the phase 3 STELLAR trials of selonsertib (NCT03053050 and NCT03053063) who completed PRO questionnaires (SF-36, CLDQ-NASH, EQ-5D, or WPAI:SHP) before treatment initiation. Results: Compared with patients with F3 fibrosis, higher proportions of patients with F4 fibrosis were female, were white, had more hematologic and gastrointestinal comorbidities, and had type 2 diabetes (P ≤ .01). Mean physical health-related PRO scores were significantly lower than those of the general population: patients with F4 fibrosis had score reductions of 4.4% to 12.9% in 6/8 SF-36 domains and patients with F3 fibrosis had score reductions of 3.9% to 11.7% in 4/8 domains (P < .01). Compared to patients with F3 fibrosis, those with F4 fibrosis had lower scores in all but 1 domains of CLDQ-NASH, Role Physical, Bodily Pain, and Social Functioning domains of the SF-36, and EQ-5D (P ≤ 01). In multivariate regression analysis, factors independently associated with lower PRO scores included having cirrhosis, female sex, higher body mass index, history of smoking, and diabetes or other comorbidities (P < .01). Conclusions: PROs are significantly lower in patients with NASH with advanced fibrosis who participated in the STELLAR clinical trials. Treatment of patients with NASH should focus on improving not only clinical outcomes but also quantifiable symptom burden and health-related quality of life.

Original languageEnglish (US)
Pages (from-to)2552-2560.e10
JournalClinical Gastroenterology and Hepatology
Issue number12
StatePublished - Nov 2019


  • BMI
  • Emotional
  • Physical Function
  • Utilities

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis'. Together they form a unique fingerprint.

Cite this